Alterations in mineral metabolism are a hallmark of CKD, which includes increases in systemic phosphate levels, also called hyperphosphatemia, as well as elevations in serum levels of fibroblast growth factor 23 (FGF23), which is a bone-derived phosphaturic hormone [28]. This evidence concerns the gene FGF23 and chronic kidney disease.